---
title: FundaMental Pharma
date: 2021-06-23T08:09:23Z
modified: 2026-08-11T10:18:11Z
permalink: "https://www.htgf.de/en/portfolio/htgffamily/fundamental-pharma/"
type: portfolio
status: publish
excerpt: ""
wpid: 89512
language:
  - English
post_translations:
  - pll_60d1cb125b9d2
branchen22:
  - Neurology
sectors:
  - Pharmaceuticals
focus_areas:
  - Neurology
  - Neuromodulation
timestamp: 2026-08-11T10:18:11Z
tags:
  - English
  - pll_60d1cb125b9d2
  - Neurology
  - Pharmaceuticals
  - Neuromodulation
---

## Beschreibungstext

FundaMental Pharma GmbH (FMP) is developing new types of drugs that act as ‘molecular spacers’ and disrupt a death signaling complex in the brain. Using this pharmacological strategy, FMP scientists succeeded in eliminating the toxic properties of the glutamate-controlled NMDA-type neurotransmitter receptor.

FMP has already identified first drug candidates that are currently in pre-clinical development and will be tested in humans within the next 2-3 years.

The discovery of an entirely new pharmacological principle (‚interface targeting‘) raises hopes that previously untreatable neurodegenerative diseases in humans can be mitigated. Interface inhibitors open up new possibilities, both in terms of drug treatments and gene therapy approaches.

FMP was established in 2016 as a biotech start-up of the Interdisciplinary Center for Neurosciences (IZN) at Heidelberg University by Professor Hilmar Bading, Junior Professor Daniela Mauceri and Dr. Thomas Schulze.

## Unternehmenswebsite

www.fundamentalpharma.com

## Adresse

FundaMental Pharma GmbH
Dr. Thomas Schulze, CEO
c/o FundaMental Pharma GmbH
Johann-Fischer-Straße 2, 69121 Heidelberg

## Kontakt

Array

Array

Array